Lipid management in chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2013 clinical practice guideline

Annals of Internal Medicine

Volumn 160, Issue 3, 2014, Pages 182-189

  Tonelli, Marcello ^a   Wanner, Christoph ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AGE DISTRIBUTION; ARTICLE; CHRONIC KIDNEY DISEASE; DIALYSIS; ENGLISH AS A SECOND LANGUAGE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; CLINICAL PRACTICE; CONSULTATION; DYSLIPIDEMIA; ESTIMATED GLOMERULAR FILTRATION RATE; HEMODIALYSIS; KIDNEY GRAFT; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS;

ADULT; ALGORITHMS; BIOLOGICAL MARKERS; CHILD; CHOLESTEROL, LDL; CORONARY DISEASE; DYSLIPIDEMIAS; GLOMERULAR FILTRATION RATE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84893859646     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/m13-2453     Document Type: Article

References (38)

1. Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825-30. [PMID: 23732715]
2. Grundy SM. Diabetes and coronary risk equivalency: what does it mean? [Editorial]. Diabetes Care. 2006;29:457-60. [PMID: 16443907]
3. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al; Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths. Lancet. 2007;370:1829-39. [PMID: 18061058]
4. Chiang CK, Ho TI, Hsu SP, Peng YS, Pai MF, Yang SY, et al. Low-density lipoprotein cholesterol: association with mortality and hospitalization in hemodialysis patients. Blood Purif. 2005;23:134-40. [PMID: 15665509]
5. Coresh J, Longenecker JC, Miller ER 3rd, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol. 1998;9:S24-30. [PMID: 11443765]
6. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887-93. [PMID: 11967041]
7. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458-82. [PMID: 2333868]
8. Krane V, Winkler K, Drechsler C, Lilienthal J, März W, Wanner C; German Diabetes and Dialysis Study Investigators. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. Am J Kidney Dis. 2009;54:902-11. [PMID: 19781835]
9. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451-9. [PMID: 14747502]
10. Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, et al; Alberta Kidney Disease Network. Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol. 2013;24:979-86. [PMID: 23687359]
11. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181-92. [PMID: 21663949]
12. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:263-75. [PMID: 22910937]
13. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al; CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009;54:810-9. [PMID: 19540640]
14. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M; Cholesterol and Recurrent Events (CARE) Trial Investigators. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ. 2006;332:1426. [PMID: 16714328]
15. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47. [PMID: 9603539]
16. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al; European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635-701. [PMID: 22555213]
17. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation. 2002;105:310-5. [PMID: 11804985]
18. Woodward M, Brindle P, Tunstall-Pedoe H; SIGN group on risk estimation. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93:172-6. [PMID: 17090561]
19. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475-82. [PMID: 18573856]
20. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-48. [PMID: 16034009]
21. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-407. [PMID: 19332456]
22. Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013;34:1807-17. [PMID: 23470492]
23. März W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E, et al; German Diabetes and Dialysis Study Investigators. Atorvastatin and lowdensity lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol. 2011;6:1316-25. [PMID: 21493741]
24. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361:2024-31. [PMID: 12814712]
25. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32:S142-56. [PMID: 9820472]
26. Bachorik PS, Ross JW. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem. 1995;41:1414-20. [PMID: 7586510]
27. Stein EA, Myers GL. National Cholesterol Education Program recommendations for triglyceride measurement: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem. 1995;41:1421-6. [PMID: 7586511]
28. Warnick GR, Wood PD. National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem. 1995;41:1427-33. [PMID: 7586512]
29. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 Suppl 5:S213-56. [PMID: 22084329]
30. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003;41:I-IV, S1-91. [PMID: 12671933]
31. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007;18:293-303. [PMID: 17167113]
32. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health [Letter]. Circ Cardiovasc Qual Outcomes. 2012;5:2-5. [PMID: 22253366]
33. Takahashi O, Glasziou PP, Perera R, Shimbo T, Suwa J, Hiramatsu S, et al. Lipid re-screening: what is the best measure and interval? Heart. 2010;96:448-52. [PMID: 19528038]
34. Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A; LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med. 2008;148:656-61. [PMID: 18458278]
35. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97. [PMID: 11368702]
36. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-95. [PMID: 15385655]
37. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al; APPROACH Investigators. The association among renal insufficiency, pharmacotherapy, and outcomes in 6, 427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587-92. [PMID: 15489090]
38. Latif F, Kleiman NS, Cohen DJ, Pencina MJ, Yen CH, Cutlip DE, et al; EVENT Investigators. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drugeluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv. 2009;2:37-45. [PMID: 19463396]